Loading
A phase 3 trial testing IBI354 in ovarian cancer, active and no longer recruiting.
Study of IBI354 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer is a phase 3 interventional study registered as NCT06834672, led by Innovent Biologics (Suzhou), and active but no longer recruiting on the registry. Official title: A Multicenter, Randomised, Open-label Phase III Study of IBI354 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer. Planned enrolment is 450 participants (estimated). The study started in 2025-03-17 and primary completion is expected in 2027-12-28. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares IBI354, Innovent Biologics.
Shares IBI354, Innovent Biologics.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/